Quarterly report · Q2
3583.TEDINET S100PIIF
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥341m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥366m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥366m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥727m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥363m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥405m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥365m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥537m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥252m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥270m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥252m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥9.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.8bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥190m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥649m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥44m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥189m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥114m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥266m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥97.39 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.08 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥194.04 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.19 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.71 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 59.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥344,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥12m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥4m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥696m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥693m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥44m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥451m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥495m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥14m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥491m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥14m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥697m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥695m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| jpcrp040300-q2r_E00584-000Medical Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥77m |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E00584-000Technological Productsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥449m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥527m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥2m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥513m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 534
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayments of lease obligations fin cf | Prior1YTDDuration | -19814000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -14709000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -19000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -20900000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -113700000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 4006000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 8504000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 585304000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 40941000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1867635000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2435227000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2452939000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2476169000 | JPY |
| Shipment expenses sga | Prior1YTDDuration | 59751000 | JPY |
| Shipment expenses sga | CurrentYTDDuration | 71435000 | JPY |
| Payrolls allowances and bonuses sga | Prior1YTDDuration | 227002000 | JPY |
| Payrolls allowances and bonuses sga | CurrentYTDDuration | 240278000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 26639000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 31315000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 7507000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 8577000 | JPY |
| Provision for jesop expense sga | Prior1YTDDuration | 10245000 | JPY |
| Provision for jesop expense sga | CurrentYTDDuration | 10118000 | JPY |
| Welfare expenses sga | Prior1YTDDuration | 36872000 | JPY |
| Welfare expenses sga | CurrentYTDDuration | 41295000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 59621000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 52381000 | JPY |
| Rent expenses sga | Prior1YTDDuration | 17891000 | JPY |
| Rent expenses sga | CurrentYTDDuration | 18014000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 2010237000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 695081000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 2705319000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1434000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2706753000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 1916000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 1916000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1916000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 2010237000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 696998000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 2707235000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1434000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2708669000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00584-000TechnologicalProductsReportableSegmentsMember | 449155000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00584-000MedicalProductsReportableSegmentsMember | 77427000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 526583000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -13991000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 512592000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |